CClinicalTrials.gg
CompletedNCT03457909Updated Sep 23, 2019Results posted

Detachable String Magnetically Controlled Capsule Endoscopy for Completely Viewing of Esophagus and Stomach

An interventional study of DS-MCE in Outpatients, sponsored by Changhai Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of the study is to determine the safety and feasibility of the new technique,detachable string magnetically controlled capsule endoscopy(DS-MCE)for evaluating gastric and esophagus diseases.

Read the detailed description

Esophageal capsule endoscopy(ECE)provides a novel noninvasive approach to visualize the esophagus.The main drawback for the use of ECE is its unreliable transit time which often renders an inadequate visualization of the esophagus.Thus investigators have developed the detachable string magnetically controlled capsule endoscopy(DS-MCE) which can control the movement of the capsule through the string.

This study is a prospective, single-centered, self-controlled pilot study.Outpatients who have esophagus symptoms will take conventional endoscopy examination and DS-MCE successively.

02

Conditions studied

  • Outpatients

Keywords

  • string
  • capsule endoscopy
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • outpatients who have esophagus symptoms.

Exclusion criteria

Exclusion Criteria:

  • known or suspected complex history of gastrointestinal obstruction, stenosis or fistula.
  • dysphagia or delayed gastric emptying.
  • known or suspected possibility of active bleeding of digestive tract.
  • a history of abdominal operation.
  • pacemaker implantation and gastrointestinal pacemaker users.
  • patients who are allergic to simethicone or pronase.
  • pregnant women,mental patients.
  • other circumstances that doctors consider inappropriate for the study.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    DS-MCE

    outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.

    Device: DS-MCE

Interventions

  • DeviceDS-MCE

    During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.

05

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Separation of Capsule and String, and Complete Viewing of Esophagus and Stomach

    evaluate the feasibility of the novel DS-MCE examination. The successful separation of the capsule and string was evaluated by the capsule entering the stomach and and the string being pulled out.Complete viewing of esophagus and stomach was evaluated by completing the procedure from the capsule being swallowed, the esophagus observed retrograde, to the string being pulled out after separating from the capsule.This primary outcome indicated how many participatns completed the DS-MCE examination successfully.

    Time frame: up to 2 weeks

Secondary outcomes

  1. Number of DS-MCE Associated Adverse Events

    evaluate the safety of DS-MCE.Record any adverse event during the procedure and after the procedure.Patients will be followed up by telephone to inquire about the symptoms of abdominal distention, abdominal pain,vomiting and other discomfort. Follow up to the end of the capsule expulsion.

    Time frame: up to 2 weeks

  2. Duration of Time Capsule is Within the Esophagus

    time from the capsule swallowed to the capsule entering the gastric cardia to examine the stomach

    Time frame: up to 2 weeks

  3. Z-line Visualization

    Z-line represents the normal esophagogastric junction where the squamous mucosa of the esophagus and columnar mucosa of the stomach meet.We can devide the Z-line into four quadrants under capsule endoscopy. Observing all the four quadrants is considered to be a complete observation of Z-line. In this study,the number of participants with at least two quadrants of Z-line visualized was used to evaluate the Z-line visulization.

    Time frame: up to 2 weeks

  4. Quality Score of Z-line Images

    grade (mild, moderate,and severe) of air-bubble and saliva interference on the Z-line view(0, no intraluminal gas bubble; 1, a few gas bubbles, no limitation of interpretation; 2, an increased amount of intraluminal foam/gas bubbles, moderate limitation of visibility; 3, an amount of foam/gas bubbles)

    Time frame: up to 2 weeks

  5. Degree of Comfort

    evaluate patient's degree of comfort throughout the procedure.Patients will be asked to fill in a questionnaire to give scores about degree of comfort throughout the procedure.Overall discomfort was scored on a scale of 0 to 10 (0, no discomfort; 10, the overall discomfort of EGD).

    Time frame: up to 2 weeks

06

Results

Posted Sep 23, 2019

Participant flow

Healthy volunteers or patients with suspected esophageal diseases were prospectively enrolled in Changhai Hospital from March 2018 to June 2018.

Participant flow — Overall Study
MilestoneDS-MCE
Started25
Completed25
Not completed0

Outcome measures

PrimaryNumber of Participants With Successful Separation of Capsule and String, and Complete Viewing of Esophagus and Stomach

evaluate the feasibility of the novel DS-MCE examination. The successful separation of the capsule and string was evaluated by the capsule entering the stomach and and the string being pulled out.Complete viewing of esophagus and stomach was evaluated by completing the procedure from the capsule being swallowed, the esophagus observed retrograde, to the string being pulled out after separating from the capsule.This primary outcome indicated how many participatns completed the DS-MCE examination successfully.

Time frame:
up to 2 weeks
Reported as:
Count of participants · Participants
Number of Participants With Successful Separation of Capsule and String, and Complete Viewing of Esophagus and Stomach
ParticipantsDS-MCE
Number of Participants With Successful Separation of Capsule and String, and Complete Viewing of Esophagus and Stomach25
SecondaryNumber of DS-MCE Associated Adverse Events

evaluate the safety of DS-MCE.Record any adverse event during the procedure and after the procedure.Patients will be followed up by telephone to inquire about the symptoms of abdominal distention, abdominal pain,vomiting and other discomfort. Follow up to the end of the capsule expulsion.

Time frame:
up to 2 weeks
Reported as:
Number · adverse events
Number of DS-MCE Associated Adverse Events
adverse eventsDS-MCE
Number of DS-MCE Associated Adverse Events0
SecondaryDuration of Time Capsule is Within the Esophagus

time from the capsule swallowed to the capsule entering the gastric cardia to examine the stomach

Time frame:
up to 2 weeks
Reported as:
Median · minutes
Duration of Time Capsule is Within the Esophagus
minutesDS-MCE
Duration of Time Capsule is Within the Esophagus6.2 (2.2 to 22.2)
SecondaryZ-line Visualization

Z-line represents the normal esophagogastric junction where the squamous mucosa of the esophagus and columnar mucosa of the stomach meet.We can devide the Z-line into four quadrants under capsule endoscopy. Observing all the four quadrants is considered to be a complete observation of Z-line. In this study,the number of participants with at least two quadrants of Z-line visualized was used to evaluate the Z-line visulization.

Time frame:
up to 2 weeks
Reported as:
Number · participants
Z-line Visualization
participantsDS-MCE
Z-line Visualization20
SecondaryQuality Score of Z-line Images

grade (mild, moderate,and severe) of air-bubble and saliva interference on the Z-line view(0, no intraluminal gas bubble; 1, a few gas bubbles, no limitation of interpretation; 2, an increased amount of intraluminal foam/gas bubbles, moderate limitation of visibility; 3, an amount of foam/gas bubbles)

Time frame:
up to 2 weeks
Reported as:
Mean · score on a scale
Quality Score of Z-line Images
score on a scaleDS-MCE
Quality Score of Z-line Images0.68 (0 to 1)
SecondaryDegree of Comfort

evaluate patient's degree of comfort throughout the procedure.Patients will be asked to fill in a questionnaire to give scores about degree of comfort throughout the procedure.Overall discomfort was scored on a scale of 0 to 10 (0, no discomfort; 10, the overall discomfort of EGD).

Time frame:
up to 2 weeks
Reported as:
Mean · score on a scale
Degree of Comfort
score on a scaleDS-MCE
Degree of Comfort0.96 (0 to 3)

Adverse events

Collected over All patients were followed up to 2 weeks to confirm capsule excretion and any adverse events.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DS-MCE0/25 (0%)0/25 (0%)0/25 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)DS-MCE
Mean54 (28 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)DS-MCE
Female7
Male18
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)DS-MCE
Region of Enrollment
Region of Enrollment(participants)DS-MCE
China25
07

Study locations

1 site
  • Changhai Hospital
    Shanghai, Shanghai 200433, China
08

References and documents

Study documents

  • Study protocol · Mar 1, 2018
  • Statistical analysis plan · Mar 1, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03457909
Lead sponsor
Changhai Hospital
Responsible party
Zhuan Liao (associate professor, Changhai Hospital) — Principal investigator
First posted
Mar 8, 2018
Start date
Mar 7, 2018
Primary completion
Jul 10, 2018
Completion
Aug 1, 2018
Results posted
Sep 23, 2019
Last update
Sep 23, 2019

Study contacts

Zhuan Liao
study chair · Changhai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion